Bacteriophage therapy of experimental bubonic plague in mice

Advances in Experimental Medicine and Biology

Volumn 954, Issue , 2012, Pages 337-348

  Filippov, Andrey A ^a   Sergueev, Kirill V ^a   He, Yunxiu ^a   Huang, Xiao Zhe ^a   Gnade, Bryan T ^a   Mueller, Allen J ^a   Fernandez Prada, Carmen M ^a   Nikolich, Mikeljon P ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ARTICLE; BACTERIOPHAGE; BAGG ALBINO MOUSE; CELL LINE; HUMAN; MOUSE; PLAGUE;

ANIMALS; BACTERIOPHAGES; CELL LINE; HUMANS; MICE; MICE, INBRED BALB C; PLAGUE;

EID: 84868160280     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-3561-7_41     Document Type: Conference Paper

References (54)

1. Abedon ST, Thomas-Abedon C (2010) Phage therapy pharmacology. Curr Pharm Biotechnol 11:28-47
2. Advier M (1933) Etude d'un bactériophage antipesteux. Bull Soc Pathol Exot 26:94-99
3. Anderson GW, Leary SEC, Williamson ED et al (1996) Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsulepositive and -negative strains of Yersinia pestis. Infect Immun 64:4580-4585
4. Bearden SW, Fetherston JD, Perry RD (1997) Genetic organization of the yersiniabactin biosynthetic region and construction of avirulent mutants in Yersinia pestis. Infect Immun 65:1659-1668
5. Biswas B, Adhya S, Washart P et al (2002) Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 70:204-210
6. Bogovazova GG, Voroshilova NN, Bondarenko VM (1991) The ef fi cacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection. Zh Mikrobiol Epidemiol Immunobiol 4:5-8
7. Byrne WR, Welkos SL, Pitt ML et al (1998) Antibiotic treatment of experimental pneumonic plague in mice. Antimicrob Agents Chemother 42:675-681
8. Capparelli R, Parlato M, Borriello G et al (2007) Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 51:2765-2773
9. Carmody LA, Gill JJ, Summer EJ et al (2010) Ef fi cacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis 201:264-271
10. Carstensen JT, Rhodes CT (eds) (2000) Drug stability: principles and practices, 3rd edn. Marcel Dekker, Inc., New York\
11. Cerveny KE, DePaola A, Duckworth DH, Gulig PA (2002) Phage therapy of local and systemic disease caused by Vibrio vulni fi cus in iron-dextran-treated mice. Infect Immun 70:6251-6262
12. Chu MC (2000) Laboratory manual of plague diagnostic tests. Centers for Disease Control and Prevention, Fort Collins, CO.\
13. Dennis DT, Gage KG (1999) Plague. In: Armstrong D, Cohen J (ed) Infectious diseases, vol. 2. Mosby, Armstrong, and Cohen, London Deresinski S (2009) Bacteriophage therapy: exploiting smaller fl eas. Clin Infect Dis 48:1096-1101
14. Duplantier J-M, Duchemin J-B, Chanteau S, Carniel E (2005) From the recent lessons of the Malagasy foci towards a global understanding of the factors involved in plague reemergence. Vet Res 36:437-453
15. Filippov AA, Sergueev KV, He Y et al (2011) Bacteriophage-resistant mutants in Yersinia pestis: identi fi cation of phage receptors and attenuation for mice. PLoS One 6(9):e25486
16. Fischetti VA (2010) Bacteriophage endolysins: a novel anti-infective to control gram-positive pathogens. Int J Med Microbiol 300:357-362
17. Freeman VJ (1951) Studies on the virulence of bacteriophage-infected strains of Corynebacterium diphtheriae. J Bacteriol 61:675-688
18. Gage KL, Kosoy MY (2005) Natural history of plague: perspectives from more than a century of research. Annu Rev Entomol 50:505-528
19. Galimand M, Guiyoule A, Gerbaud G et al (1997) Multiple antibiotic resistance in Yersinia pestis mediated by a self-transferable plasmid. N Engl J Med 337:677-680
20. Galimand M, Carniel E, Courvalin P (2006) Resistance of Yersinia pestis to antimicrobial agents. Antimicrob Agents Chemother 50:3233-3236
21. Garcia E, Elliott JM, Ramanculov E et al (2003) The genome sequence of Yersinia pestis bacteriophage f A1122 reveals an intimate history with the coliphage T3 and T7 genomes. J Bacteriol 185:5248-5262
22. Garcia E, Chain P, Elliott JM et al (2008) Molecular characterization of L-413C, a P2-related plague diagnostic bacteriophage. Virology 372:85-96
23. Gill JJ, Hyman P (2010) Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol 11:2-14
24. Gill JJ, Pacan JC, Carson ME et al (2006) Ef fi cacy and pharmacokinetics of bacteriophage therapy in treatment of subclinical Staphylococcus aureus mastitis in lactating dairy cattle. Antimicrob Agents Chemother 50:2912-2918
25. Guiyoule A, Gerbaud G, Buchrieser C et al (2001) Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg Infect Dis 7:43-48
26. Hagens S, Loessner MJ (2010) Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations. Curr Pharm Biotechnol 11:58-68
27. Heo YJ, Lee YR, Jung HH et al (2009) Antibacterial ef fi cacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob Agents Chemother 53:2469-2474
28. Hinnebusch BJ, Rosso M-L, Schwan TG, Carniel E (2002) High-frequency conjugative transfer of antibiotic resistance genes to Yersinia pestis in the fl ea midgut. Mol Microbiol 46:349-354
29. Housby JN, Mann NH (2009) Phage therapy. Drug Discov Today 14:536-540
30. Imamaliev OG, Serebryakova VG, Anisimova TI et al (1986) Comparative estimation of activity and speci fi city of diagnostic plague bacteriophages, L-413C and Pokrovskaya. In: Bektemirov TA, Zhouravleva YZ, Litvinova MY (eds) Standards, strains, and methods of control of bacterial and viral preparations. Mechnikov Institute Press, Moscow, pp 102-106
31. Inglesby TV, Dennis DT, Henderson DA et al (2000) Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense JAMA 283:2281-2290
32. Iteman I, Guiyoule A, de Almeida AM et al (1993) Relationship between loss of pigmentation and deletion of the chromosomal iron-regulated irp2 gene in Yersinia pestis: evidence for separate but related events. Infect Immun 61:2717-2722
33. Korzeniewski C, Callewaert DM (1983) An enzymerelease assay for natural cytotoxicity. J Immunol Methods 64:313-320
34. Kutter E, De Vos D, Gvasalia G et al (2010) Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 11:69-86
35. Larina VS, Anisimov PI, Adamov AK (1970) A novel strain of plague bacteriophage for identi fi cation of Pasteurella pestis. Probl Particularly Dangerous Infect 11:132-136
36. Levin BR, Bull JJ (2004) Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol 2: 166-173
37. Lukaszewski RA, Kenny DJ, Taylor R et al (2005) Pathogenesis of Yersinia pestis infection in BALB/c mice: effects on host macrophages and neutrophils. Infect Immun 73:7142-7150
38. Marza JA, Soothill JS, Boydell P, Collyns TA (2006) Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 32:644-646
39. McVay CS, Velásquez M, Fralick JA (2007) Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51:1934-1938
40. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
41. Muniesa M, Jofre J (1998) Abundance in sewage of bacteriophages that infect Escherichia coli O157:H7 and that carry the Shiga toxin 2 gene. Appl Environ Microbiol 64:2443-2448
42. Naumov AV, Samoilova LV (eds) (1992) Manual on prophylaxis of plague. Russian Research Anti-Plague Institute "Microbe" Press, Saratov No authors listed (1992) Centers for Disease Control and Prevention. Pneumonic plague - Arizona. JAMA 268:2146-2147
43. Perry RD, Fetherston JD (1997) Yersinia pestis - etiologic agent of plague. Clin Microbiol Rev 10:35-66
44. Pokrovskaya MP (1929) A plague bacteriophage in dead susliks. Gigiena Epidemiol 12:31-34
45. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY Scho fi eld DA, Molineux IJ, Westwater C (2009) Diagnostic bioluminescent phage for detection of Yersinia pestis. J Clin Microbiol 47:3887-3894
46. Sergueev KV, He Y, Borschel RH et al (2010) Rapid and sensitive detection of Yersinia pestis using ampli fi cation of plague diagnostic bacteriophages monitored by real-time PCR. PLoS ONE 5(6):e11337
47. Skurnik M, Strauch E (2006) Phage therapy: facts and fi ction. Intern J Med Microbiol 296:5-14
48. Soothill JS (1992) Treatment of experimental infections of mice with bacteriophages. J Med Microbiol 37:258-261
49. Waldor M, Mekalanos J (1996) Lysogenic conversion by a fi lamentous phage encoding cholera toxin. Science 272:1910-1914
50. Watanabe R, Matsumoto T, Sano G et al (2007) Ef fi cacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 51:446-452
51. Welch TJ, Fricke WF, McDermott PF et al (2007) Multiple antimicrobial resistance in plague: an emerging public health risk. PLoS One 2(3):e309
52. Welkos S, Pitt ML, Martinez M et al (2002) Determination of the virulence of the pigmentation-de fi cient and pigmentation/plasminogen activator-de fi cient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague. Vaccine 20:2206-2214
53. Zhao X, Wu W, Qi Z et al (2010) The complete genome sequence and proteomics of Yersinia pestis phage Yep-phi. J Gen Virol 92:216-221
54. Zietz BP, Dunkelberg H (2004) The history of the plague and the research on the causative agent Yersinia pestis. Int J Hyg Environ Health 207:165-178